Phase II Trial of Gefitinib in Combination With Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer With Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

Journal of Thoracic Oncology - United States
doi 10.1097/jto.0000000000000434
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non–Small-Cell Lung Cancer With Sensitizing EGFR Mutation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

140PD: LUX-Lung 7: A Phase IIb, Global, Randomised, Open-Label Trial of Afatinib vs Gefitinib as First-Line Treatment for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harbouring Activating EGFR Mutations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients With Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients With Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

Randomized Phase II Trial of Seribantumab in Combination With Erlotinib in Patients With EGFR Wild‐Type Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2010English

Combination of Chemotherapy and Gefitinib as First-Line Treatment for Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: A Randomized Controlled Trial

International Journal of Cancer
Cancer ResearchOncology
2017English

Trial-Based Cost-Utility Analysis of Icotinib Versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China

PLoS ONE
Multidisciplinary
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy